An integrated approach to MS-based identification and risk assessment of pharmaceutical biotransformation in wastewater.

The omnipresence of pharmaceuticals at relatively high concentrations (μg/L) in environmental compartments indicated their inadequate removal by wastewater treatment plants. As such, batch reactors seeded with activated sludge were set up to assess the biotransformation of metformin, ranitidine, lidocaine and atorvastatin. The main objective was to identify transformation products (TPs) through the establishment of an integrated workflow for suspect and non-target screening based on reversed phase liquid chromatography quadrupole-time-of-flight mass spectrometry.